Dillon & Associates Inc. Has $3.54 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Dillon & Associates Inc. lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 24,426 shares of the company’s stock after selling 121 shares during the quarter. Dillon & Associates Inc.’s holdings in Johnson & Johnson were worth $3,542,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of JNJ. IFS Advisors LLC grew its holdings in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares in the last quarter. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $29,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $32,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $35,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Barclays boosted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Morgan Stanley decreased their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Trading Up 0.2 %

JNJ stock opened at $163.40 on Monday. The company has a market cap of $393.76 billion, a P/E ratio of 24.57, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The business has a fifty day moving average of $156.99 and a 200-day moving average of $156.17.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the company posted $2.29 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.